Pharmafile Logo
Pharmafocus logo
Advanced Search

Seattle Genetics

Showing 10 posts of 10 posts found.

shutter

MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn

September 15, 2020
Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma

MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …

News
astellas_tokyo_copy_9

FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug

December 19, 2019
Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer

The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …

News
iannone

Immunomedics’ whirlwind in the C-suite continues

April 10, 2018
Manufacturing and Production, Medical Communications AstraZeneca, Immunomedics, Seattle Genetics, biotech, drugs, pharma, pharmaceutical

Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …

News

Seattle Genetics gain breakthrough therapy designation

March 26, 2018
Manufacturing and Production, Sales and Marketing Astellas, Seattle Genetics, biotech, drugs, pharma, pharmaceutical

Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy …

News
seattle_gen

Seattle in $614m move for Cascadian Therapeutics

January 31, 2018
Sales and Marketing Cascadian Theapeutics, HER2, Seattle Genetics, biotech, drugs, pharma, pharmaceutical

Things don’t always go quite according to plan in the biotech world – something both Seattle Genetics and Cascadian Therapeutics …

News
office-space-1988480_960_720

Board battle scuppers Seattle Genetics’ $2 billion licensing deal

May 8, 2017
Sales and Marketing Immunomedics, Seattle Genetics, venBio

In another example of the influence that activist investors can have on the direction of a business, the potentially $2 …

News
seattle_genetics

Seattle Genetics’ prospective $2 billion licensing deal not without controversy

February 13, 2017
Sales and Marketing Immunomedics, Seattle Genetics, enVio

Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …

News
seattle_genetics

Four die in Seattle Genetics’ drug trial

January 3, 2017
Manufacturing and Production, Medical Communications, Sales and Marketing Seattle Genetics, patient deaths, trial hold

Seattle Genetics released that the FDA had placed a hold had been placed on clinical trials involving its experimental cancer …

News
takeda_tokyo_hq

Phase III success for Takeda in lymphoma drug

August 1, 2016
Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma

Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …

News

Blood cancer drug Adcetris approved by FDA

August 24, 2011
Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma

The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …

News

Latest content

Roche to acquire Carmot Therapeutics for $2.7bn

December 4, 2023

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023